Treatment caused a dose-dependent increase in the total protein levels of LC3A/B, Beclin-1 (Atg6), Atg5, Atg7, and Atg16L1 in BT-474 breast cancer cells (Figure 5B). The gene discussed is BECN1; the disease is breast carcinoma.